


Wockhardt appoints Dr Yatendra as president-R&D

10 May 2005 | News



Wockhardt, a pharmaceutical and biotechnology major, has appointed Dr Yatendra Kumar as president-R&D, to drive its growth in the US and European generic formulations and active pharmaceutical ingredients (API) markets. Dr Kumar has over 100 patents in his name and has published 22 research papers during a long research career in American universities and Astra of Sweden.

Pfizer names Kewal Handa its MD

Pfizer has announced that Kewal Handa has been appointed as managing director, Pfizer Ltd, India. Prior to this,  served as executive director-Finance, Pfizer Ltd. He succeeds Hocine Sidi Said as the leader of the Pfizer's India operations who had spent four years in India as managing director.

During his fifteen years with the company, Kewal Handa has been entrusted with positions of increasing responsibility. He has a broad range of experience and has risen above his portfolio as Chief Financial Officer (CFO) by being a key contributor to shaping the future of Pfizer. He has demonstrated leadership and excellence in strategically guiding Pfizer Limited through two mergers with Parke Davis - Warner Lambert (India) Private Limited and Pharmacia.

Handa is recognized as an industry expert on issues concerning the pharmaceutical sector. As chairman of the Pricing Committee of the Organization of Pharmaceutical Producers of India (OPPI), he has been at the forefront of the industry's efforts to resolve issues pertaining to the pharmaceutical sector.

Handa is also a committee member of the Confederation of Indian Industry (CII), Indian Pharmaceutical Alliance (IPA) and the Bombay Chamber of Commerce and Industry (BCCI). He currently serves as president of the Bombay Management

Association (BMA). He was recently awarded the 'India CFO 2004-Excellence in Finance in MNC' by the International Market Assessment Group

Lupin appoints Dr Sudershan Arora as president of NCE research

Lupin Ltd has appointed Dr Sudershan Arora as president of NCE research. In his earlier stint in Lupin, Dr Arora had led the company into filing four new drug applications for NCE, including Psoriasis and Tuberculosis. These molecules are at different stages of clinical trials.

"The company takes great pleasure in welcoming back Dr Arora and will benefit immensely from his vast knowledge and rich experience in the area of NCE research," Dr D B Gupta, chairman of Lupin Ltd, said.